Levetiracetam (Keppra)

Levetiracetam, marketed under the human brand name Keppra, is a modern anticonvulsant medication that has become increasingly valuable in equine medicine for the management of seizure disorders. This medication represents a significant advancement over older anticonvulsants due to its unique mechanism of action, favorable safety profile, and minimal drug interactions. Originally developed for human epilepsy treatment, levetiracetam has found an important niche in equine neurology, particularly for managing seizures in foals with neonatal maladjustment syndrome and in adult horses with epilepsy or acute neurological crises requiring seizure control.

The mechanism by which levetiracetam prevents seizures differs from traditional anticonvulsants and is not completely understood. The medication binds to synaptic vesicle protein 2A (SV2A), which is involved in the release of neurotransmitters from nerve terminals. By modulating this protein, levetiracetam appears to reduce abnormal synchronous neuronal firing that characterizes seizure activity without significantly affecting normal brain function. This unique mechanism may explain why levetiracetam often remains effective in cases where other anticonvulsants have failed and why it produces fewer cognitive and sedative side effects than many traditional seizure medications.

Levetiracetam is available in multiple formulations including tablets, an oral solution, and an injectable form for intravenous administration. The availability of an injectable preparation is particularly valuable in equine emergency situations where rapid seizure control is needed and oral administration is not practical. The oral formulations allow for convenient long-term management once acute seizures are controlled. The medication can be given with or without food, and the oral solution provides flexibility for dose adjustments and administration to horses that are difficult to medicate with tablets.

The safety profile of levetiracetam in horses is considered favorable, though the medication is used off-label as it is not FDA-approved for veterinary species. Unlike many older anticonvulsants, levetiracetam does not require routine blood level monitoring and does not cause significant hepatotoxicity or bone marrow suppression. The medication is primarily eliminated by the kidneys, with some hydrolysis occurring independently of liver enzymes. This pharmacokinetic profile results in minimal drug interactions, making levetiracetam particularly useful in horses receiving multiple medications. Veterinary supervision remains essential for appropriate dosing, monitoring, and ensuring the medication is suitable for each individual patient.

The primary indication for levetiracetam in equine medicine is the control and prevention of seizures, with neonatal foals representing a particularly important patient population. Foals with neonatal maladjustment syndrome, also known as dummy foal syndrome or hypoxic-ischemic encephalopathy, frequently experience seizures as part of their neurological dysfunction. Levetiracetam has become a first-line treatment option for these critically ill foals due to its rapid onset of action when given intravenously, favorable safety profile in neonates, and lack of the significant sedation that complicates assessment of neurological status. The medication helps control acute seizure activity while the underlying brain injury heals.

Adult horses with epilepsy, though relatively uncommon, represent another important population for levetiracetam therapy. True epilepsy in horses manifests as recurrent seizures without an identifiable acute cause, and affected horses require long-term anticonvulsant therapy. Levetiracetam offers advantages for maintenance therapy due to its minimal effects on cognitive function, lack of hepatotoxicity with chronic use, and favorable drug interaction profile. Horses on levetiracetam can often maintain more normal activity levels and demeanor compared to those on older sedating anticonvulsants, which is particularly important for horses with roles as companions, breeding animals, or light pleasure mounts.

Status epilepticus and acute symptomatic seizures in horses of any age may be treated with levetiracetam, often as part of a multi-drug protocol. When horses experience seizures secondary to acute neurological disease, metabolic disturbances, or toxic exposures, rapid seizure control is essential to prevent further brain damage and injury from seizure-related trauma. The intravenous formulation of levetiracetam allows for immediate administration in emergency situations, and the medication can be used in combination with benzodiazepines or other anticonvulsants when single-agent therapy is insufficient.

Secondary applications of levetiracetam in horses include prophylactic use in patients at high risk for seizures and adjunctive therapy in horses with incompletely controlled seizures on other medications. Horses recovering from head trauma, undergoing certain surgical procedures, or experiencing severe metabolic derangements may receive prophylactic levetiracetam to reduce seizure risk. For horses with breakthrough seizures despite other anticonvulsant therapy, adding levetiracetam may improve seizure control without the significant drug interactions that complicate adding many other anticonvulsants.

The decision to use levetiracetam rather than alternative anticonvulsants depends on multiple factors including the clinical situation, patient age, concurrent medications, and need for rapid onset of action. Levetiracetam is often preferred when minimal sedation is desired, when the patient is receiving multiple other medications, or when the intravenous route of administration is advantageous. Cost considerations may influence treatment decisions for long-term therapy, as levetiracetam remains more expensive than some older generic anticonvulsants. The veterinarian will recommend the most appropriate anticonvulsant based on the individual patient's circumstances.

Dosing of levetiracetam in horses requires veterinary determination based on the individual patient's weight, clinical condition, and treatment goals. The medication is used off-label in horses, and dosing protocols have been developed based on pharmacokinetic studies, clinical experience, and extrapolation from other species. Accurate body weight measurement is essential for proper dosing, particularly in foals where weight can change rapidly and in critically ill patients where dosing precision is paramount. A livestock scale provides the most accurate weight, though careful estimation using a weight tape is acceptable when scales are not available.

General dosing guidelines for levetiracetam in adult horses typically range from 20 to 60 milligrams per kilogram of body weight, depending on the clinical situation and administration route. Loading doses at the higher end of this range may be used for acute seizure control, followed by lower maintenance doses. Treatment frequency varies from twice daily to three times daily based on the formulation used and pharmacokinetic considerations. Foal dosing follows similar weight-based calculations but may require adjustment based on the neonate's developmental stage and any concurrent health conditions affecting drug metabolism.

Treatment duration depends entirely on the underlying condition and clinical response. For foals with neonatal maladjustment syndrome, treatment typically continues until the foal has been seizure-free for an appropriate period and neurological function has normalized, often spanning days to weeks. Adult horses with epilepsy may require lifelong anticonvulsant therapy, with periodic reassessment to determine the minimum effective dose. When levetiracetam is used for acute symptomatic seizures, treatment continues until the underlying cause is resolved and the risk of seizure recurrence has diminished.

Administration methods differ between the available formulations. Intravenous levetiracetam is diluted in compatible fluids and administered as a slow infusion over at least 15 minutes; rapid IV administration should be avoided. Oral tablets can be crushed and mixed with water or a palatable carrier such as applesauce for administration via oral syringe, or may be hidden in treats for horses that accept this method. The oral solution can be measured precisely and given directly or mixed with a small amount of feed. Timing of doses should be consistent each day, with doses spaced evenly to maintain stable blood levels.

Missed doses should be given as soon as remembered, unless it is nearly time for the next scheduled dose. Skipping the missed dose and resuming the regular schedule is preferable to doubling up on doses. Missing multiple doses increases the risk of breakthrough seizures in horses dependent on the medication for seizure control, and the veterinarian should be contacted if doses are frequently missed or if seizure activity recurs. Maintaining a medication log helps ensure consistent dosing and provides valuable information for veterinary consultations.

Discontinuation of levetiracetam after extended use should be done gradually under veterinary supervision rather than stopped abruptly. Sudden discontinuation of anticonvulsant therapy can precipitate breakthrough seizures, potentially including status epilepticus, even in patients whose seizures have been well-controlled. The veterinarian will develop an appropriate tapering schedule based on the duration of therapy, the underlying condition, and individual patient factors. If seizures recur during the tapering process, the veterinarian may recommend continuing therapy at an effective dose.

Levetiracetam is generally well-tolerated in horses, with a favorable side effect profile compared to many older anticonvulsants. The medication's unique mechanism of action appears to result in fewer cognitive and behavioral effects than traditional seizure medications, allowing horses to remain more alert and interactive during treatment. However, adverse effects can occur, and owners should be aware of what to monitor during therapy. Most side effects are dose-related and may resolve with dose adjustment.

The most commonly reported side effects of levetiracetam in horses include mild sedation, lethargy, and decreased appetite, particularly during the initial treatment period or following dose increases. These effects are typically less pronounced than with barbiturate anticonvulsants and often diminish as the horse adjusts to the medication. Some horses may appear quieter than normal or show reduced interest in their surroundings, but significant impairment of alertness or ability to function normally is uncommon at appropriate doses. Mild incoordination has been reported in some horses but is generally not severe enough to pose safety concerns.

Gastrointestinal effects including decreased appetite, mild colic signs, or changes in manure consistency may occur in some horses. These effects are usually self-limiting but should be monitored, particularly in horses already at risk for gastrointestinal complications. Ensuring adequate hydration and maintaining normal feeding routines can help minimize gastrointestinal upset. Significant or persistent gastrointestinal signs warrant veterinary evaluation to rule out other causes and to assess whether dose adjustment is needed.

Serious adverse effects from levetiracetam are uncommon in horses but can occur. Behavioral changes including aggression, irritability, or anxiety have been reported in human patients and may occasionally occur in horses, though this appears to be rare. Allergic reactions are possible with any medication and would manifest as hives, facial swelling, or respiratory difficulty. Any signs of a severe allergic reaction require immediate veterinary attention. Because levetiracetam is primarily eliminated by the kidneys, horses with significant renal impairment may experience drug accumulation and increased risk of adverse effects.

Rare adverse effects reported in other species that horse owners should be aware of include blood cell abnormalities and, with long-term use in humans, potential effects on bone density. These effects have not been specifically documented in horses, but periodic monitoring during long-term therapy may be prudent. Any unexplained changes in the horse's health status during levetiracetam therapy should prompt veterinary consultation. The veterinarian can help distinguish medication-related effects from other health issues and determine whether treatment modifications are needed.

Levetiracetam is contraindicated in horses with known hypersensitivity to the medication or any component of the formulation. While true allergic reactions to levetiracetam are rare, any horse that has experienced signs of hypersensitivity including hives, angioedema, respiratory difficulty, or anaphylaxis following previous administration should not receive the medication again. Owners should inform the veterinarian of any previous adverse reactions to levetiracetam or other anticonvulsants before treatment is initiated.

Significant kidney dysfunction represents an important consideration for levetiracetam use, though it may not be an absolute contraindication depending on the severity and the clinical need for seizure control. Because levetiracetam is eliminated primarily through the kidneys, horses with impaired renal function will clear the drug more slowly, leading to higher blood levels and increased risk of adverse effects. Horses with known kidney disease, elevated creatinine or BUN levels, or other indicators of reduced renal function require careful evaluation before levetiracetam administration. If the medication is necessary in such patients, dose reduction and careful monitoring are essential.

Pregnancy and lactation require consideration when contemplating levetiracetam use. The safety of levetiracetam during equine pregnancy has not been established, and the medication should be used in pregnant mares only when the benefits clearly outweigh the potential risks to the developing fetus. Human data indicate that levetiracetam crosses the placenta and is present in breast milk, and similar distribution is expected in horses. Foals nursing from mares receiving levetiracetam may be exposed to the medication through milk. Breeding animals should be evaluated carefully, and the decision to treat should account for reproductive considerations.

Other contraindications and precautions relate to specific clinical situations rather than absolute prohibition of use. Horses in active competition face regulatory restrictions, as levetiracetam is prohibited under most equestrian governing body rules. Patients with behavioral issues including a history of aggression may warrant careful observation, given reports of behavioral changes in humans taking the medication. Horses with multiple concurrent health conditions require comprehensive evaluation to ensure levetiracetam is appropriate within the context of their overall medical management. The veterinarian will assess all relevant factors when determining whether levetiracetam is suitable for a particular patient.

One of the significant advantages of levetiracetam compared to many other anticonvulsants is its minimal potential for drug interactions. The medication does not significantly induce or inhibit hepatic cytochrome P450 enzymes, which are responsible for metabolizing many drugs. This characteristic makes levetiracetam particularly valuable in horses receiving multiple medications, as the complex interactions that can occur with enzyme-inducing anticonvulsants like phenobarbital are largely avoided. Nonetheless, certain interactions warrant awareness.

Concurrent use of levetiracetam with other central nervous system depressants may result in additive sedative effects. While levetiracetam itself produces less sedation than many anticonvulsants, combining it with sedatives, tranquilizers, or other anticonvulsants can increase the overall level of central nervous system depression. Medications commonly used in equine practice that may interact in this manner include acepromazine, detomidine, xylazine, and benzodiazepines. When horses receiving levetiracetam require sedation for procedures, dose adjustments of the sedative may be needed, and recovery should be monitored carefully.

Levetiracetam can generally be combined safely with other anticonvulsants when multi-drug therapy is needed for seizure control. Unlike phenobarbital, which can alter the metabolism of numerous other medications, levetiracetam is unlikely to affect blood levels of co-administered drugs. This allows veterinarians to add levetiracetam to existing anticonvulsant regimens without significant concern for pharmacokinetic interactions. However, pharmacodynamic interactions (additive effects on brain function) remain possible, and careful dose titration is still important when combining anticonvulsants.

Regulatory considerations for competition horses extend beyond typical drug interactions. Levetiracetam is a prohibited substance under FEI, USEF, and racing commission rules, and horses receiving this medication cannot compete until appropriate withdrawal times have elapsed. The combination of levetiracetam with other medications does not alter its prohibited status, but the presence of multiple prohibited substances can result in additional scrutiny and penalties. Horse owners and trainers should maintain detailed medication records and consult with their veterinarian and regulatory officials to ensure compliance with all applicable rules. Detection times for levetiracetam can extend for a considerable period after the last dose, making early planning essential for horses that will eventually return to competition.

Monitoring requirements for horses receiving levetiracetam vary based on the clinical situation and duration of therapy. During acute seizure management, close neurological observation is essential to assess treatment efficacy and detect any breakthrough seizure activity. Vital signs including heart rate, respiratory rate, and temperature should be monitored regularly, particularly in critically ill patients. For horses on long-term oral therapy, periodic veterinary examinations help ensure continued efficacy and identify any emerging side effects. Baseline and periodic blood work, including kidney function assessment, may be recommended for horses receiving extended treatment.

Special populations require additional consideration when using levetiracetam. Neonatal foals represent the most common equine population receiving this medication, and these patients require intensive monitoring due to their underlying illness and developmental immaturity. Drug metabolism and elimination may differ in neonates compared to adult horses, potentially affecting optimal dosing. Geriatric horses may have reduced kidney function even without clinical signs of renal disease, warranting dose adjustment and careful monitoring. Horses with concurrent illness affecting multiple organ systems require comprehensive assessment to ensure levetiracetam is appropriate within their overall treatment plan.

Competition and performance horse considerations are critical for levetiracetam, as the medication is prohibited under essentially all equestrian regulatory frameworks. The FEI classifies levetiracetam as a prohibited substance, as do USEF and state racing commissions. Detection times in horses have not been extensively published, and conservative withdrawal periods should be observed. Horses with controlled seizure disorders may be unable to return to competition safely without medication, and such cases require careful discussion between the owner, veterinarian, and potentially regulatory officials. Documentation of all medication administration is essential, and any horse with a history of seizures faces additional scrutiny regarding fitness to compete.

Administration precautions include ensuring accurate dosing, proper storage of the medication, and appropriate handling of the injectable formulation. Intravenous levetiracetam should be administered as a diluted, slow infusion rather than a rapid bolus injection. Oral formulations should be administered with attention to ensuring complete consumption when mixed with feed. Human exposure to levetiracetam during handling is not typically a significant concern, but reasonable precautions such as hand washing after administration are appropriate.

Long-term use of levetiracetam requires periodic reassessment of the treatment plan. The veterinarian will evaluate whether ongoing therapy remains necessary and whether the current dose continues to provide optimal seizure control with minimal side effects. For horses with structural brain lesions or true epilepsy, lifelong therapy may be needed, but periodic attempts at dose reduction under veterinary supervision can help identify the minimum effective dose. Any changes to the treatment regimen should be made gradually and with close monitoring for seizure recurrence.

Proper storage of levetiracetam ensures medication stability and efficacy throughout the treatment period. Oral formulations including tablets and the liquid solution should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit, protected from excessive heat, moisture, and light. In barn environments, storing medication in a climate-controlled area such as a tack room with temperature regulation is preferable to locations subject to temperature extremes. The oral solution should not be frozen and should be kept in its original container with the cap tightly closed.

The injectable formulation of levetiracetam has specific storage requirements that must be followed to maintain sterility and potency. Unopened vials are typically stored at room temperature protected from light. Once a vial is opened or diluted for infusion, the solution should be used within the time frame specified by the manufacturer or pharmacist, as sterility cannot be guaranteed indefinitely after opening. Unused portions of opened vials should be discarded according to proper disposal guidelines. Diluted solutions prepared for infusion should be administered within the recommended time frame and should not be saved for later use.

Handling levetiracetam does not require special protective equipment for routine administration, but basic hygiene practices should be followed. Wash hands before and after handling the medication, and avoid unnecessary contact with the tablets or solution. If the oral solution spills on skin, wash the area with soap and water. Tablets that are crushed for administration should be handled carefully to minimize dust, and any spilled powder should be cleaned up promptly. The medication should be stored out of reach of children and animals not intended to receive treatment.

Expired levetiracetam should not be used, as medication potency and safety cannot be guaranteed past the expiration date. Outdated tablets, oral solution, or injectable medication should be disposed of properly rather than discarded in household trash or poured down drains. Many veterinary clinics and pharmacies participate in medication take-back programs, and community disposal events may also be available. Proper disposal prevents environmental contamination and reduces the risk of accidental exposure. The veterinarian or pharmacist can provide information about local options for medication disposal.

Draft horses and other large breeds require attention to accurate weight-based dosing when levetiracetam is prescribed. These horses may weigh 1,600 to 2,200 pounds or more, representing significantly greater body mass than the typical light horse. Accurate weight determination using a livestock scale is ideal, though a properly used weight tape can provide reasonable estimates for dosing calculations. The large doses required for these horses have practical and cost implications that should be discussed with the veterinarian. There are no known breed-specific sensitivities to levetiracetam in draft horses, and the medication can be used safely when dosed appropriately for body weight.

Light horses and warmbloods represent the majority of adult horses receiving levetiracetam for seizure disorders, and standard dosing guidelines typically apply to these breeds. Individual variation in drug response exists regardless of breed, and dose titration based on clinical response is appropriate for all patients. Performance horses in these categories face regulatory restrictions on levetiracetam use, and owners should verify current rules with the relevant governing body before treating horses that may return to competition. There are no established breed-specific differences in levetiracetam efficacy or safety among light horse breeds.

Ponies and miniature horses require precise dosing due to their smaller body size, and the available formulations may not be ideally suited for very small patients. The oral solution allows for accurate measurement of smaller doses, making it often the preferred formulation for ponies and miniatures. Pharmacokinetic differences between small equines and larger horses have not been extensively studied for levetiracetam, and veterinarians may use conservative dosing with careful clinical monitoring. These smaller equines are prone to metabolic conditions, but these do not directly affect levetiracetam use.

Breed-specific genetic conditions generally do not alter levetiracetam dosing or safety recommendations. Unlike some other medications that require specific precautions in breeds carrying genes for hyperkalemic periodic paralysis, malignant hyperthermia, or other genetic disorders, levetiracetam has no established contraindications based on breed genetics. However, horses with any genetic condition affecting overall health status may require individualized assessment of their suitability for any medication. Arabian foals with conditions such as severe combined immunodeficiency obviously have comprehensive health concerns that extend far beyond anticonvulsant therapy. The veterinarian will consider all relevant breed-related and individual factors when developing treatment plans that include levetiracetam.

Several alternative anticonvulsant medications are available for horses when levetiracetam is not appropriate or when additional seizure control is needed. Phenobarbital remains one of the most commonly used anticonvulsants in equine medicine, offering effective seizure control at relatively low cost. However, phenobarbital causes more sedation than levetiracetam, requires therapeutic drug monitoring, and has significant potential for drug interactions due to hepatic enzyme induction. Diazepam and midazolam are benzodiazepine anticonvulsants commonly used for acute seizure control but are less suitable for long-term maintenance therapy due to the development of tolerance.

Gabapentin and pregabalin, while primarily used for neuropathic pain in horses, also have anticonvulsant properties and may be used in certain situations. Potassium bromide has historical use as an anticonvulsant in horses but is less commonly prescribed currently due to concerns about toxicity and the availability of newer options. Newer anticonvulsants used in human medicine, such as zonisamide and lacosamide, have limited documentation in horses but may represent future options as veterinary experience accumulates. The choice between anticonvulsants depends on the specific clinical situation, patient factors, and practical considerations.

Complementary approaches to seizure management in horses focus primarily on identifying and addressing underlying causes when possible. Metabolic disturbances, infectious diseases, and toxic exposures that trigger seizures require specific treatment beyond anticonvulsant therapy. Supportive care including maintaining adequate hydration, nutrition, and a safe environment for horses experiencing seizures is essential regardless of which anticonvulsant is used. Environmental modifications to reduce injury risk during seizures, such as padded walls in foaling stalls for at-risk foals, complement pharmacological management.

Medication substitutions should never be made without veterinary guidance, as switching anticonvulsants requires careful planning to avoid breakthrough seizures. If levetiracetam is not available or must be discontinued, the veterinarian will develop an appropriate transition plan that may involve overlapping the new and old medications during a transition period. Abrupt changes in anticonvulsant therapy can precipitate life-threatening seizure activity, and even routine dose adjustments should be discussed with the veterinarian. Regular communication with the veterinary team ensures optimal seizure management for each individual patient.